Hamang Patel, MD
Advanced Heart Failure and Transplant Cardiology · New Orleans, LANPI 1801842158
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Abbott at 48.5% of the total. 2025 is the largest year on record at $911, 2.5 times the $370 reported in 2019.
Across 47 payments — averaging $55.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Abiomed$390
- Cvrx, Inc.$289
- Edwards Lifesciences$189
- Bayer$129
- AstraZeneca$93
- plus $255 from 9 others
Across 5 payments — averaging $4219.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$21K
- Merck$450
What the payments were for
- Food & beverage$2,613100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 15 | $1,267 |
| Abiomed | 5 | $390 |
| Cvrx, Inc. | 4 | $289 |
| Edwards Lifesciences | 1 | $189 |
| Bayer | 5 | $129 |
| AstraZeneca | 5 | $93 |
| Impulse Dynamics (USA) Inc. | 1 | $73 |
| Novartis | 3 | $53 |
| Procyrion, Inc. | 1 | $27 |
| Merck | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Johnson & Johnson | 2 | $20 |
| Boehringer Ingelheim | 1 | $17 |
| Ancora Heart, Inc. | 1 | $15 |
| Ambu Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few advanced heart failure and transplant cardiology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 125 | $150,633 |
| JardianceEmpagliflozin | 123 | $134,681 |
| EliquisApixaban | 57 | $54,310 |
| Envarsus XrTacrolimus | 28 | $51,824 |
| FarxigaDapagliflozin Propanediol | 31 | $39,479 |
| Tacrolimus | 176 | $35,268 |
| Repatha SureclickEvolocumab | 38 | $20,353 |
| Mycophenolic AcidMycophenolate Sodium | 20 | $17,134 |
| PrografTacrolimus | 11 | $15,230 |
| Mycophenolate Mofetil | 106 | $14,643 |
| Sirolimus | 48 | $9,024 |
| Potassium Chloride | 50 | $2,138 |
| Torsemide | 87 | $1,971 |
| Rosuvastatin Calcium | 114 | $1,859 |
| Atorvastatin Calcium | 215 | $1,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $53 | $150,633125 claims |
| Boehringer IngelheimJardiance | $17 | $134,681123 claims |
| AstraZenecaFarxiga | $93 | $39,47931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in New Orleans
- Clement EiswirthNew Orleans$277K
- Senthil AnandNew Orleans$51K
- Hector VenturaNew Orleans$39K
- Sapna DesaiNew Orleans$30K
- Selim KrimNew Orleans$9K
- Frank SmartNew Orleans$4K
- Adam LickNew Orleans$2K
- Thierry LejemtelNew Orleans$506
- Peter FailHouma$206K
- Shane PrejeanHouma$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.